Form 4: Monopar Therapeutics' Chief Operating Officer Increases Stake in Company

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, recently purchased 24,000 shares of the company's common stock.

Summary

• On June 3, 2024, Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, purchased 12,000 shares of common stock at a price of $0.76 per share.
• Following this transaction, Mr. Cittadine directly owned 105,624 shares of Monopar Therapeutics.
• On June 4, 2024, Mr. Cittadine purchased an additional 12,000 shares of common stock at a price of $0.78 per share.
• Following this second transaction, Mr. Cittadine directly owned 117,624 shares of Monopar Therapeutics.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to insider buying, which often signals confidence in the company's future. However, the purchases are relatively small and may not be indicative of a major shift in sentiment.

Positives

• The Chief Operating Officer's purchase of shares may signal confidence in the company's future prospects.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company insider believes the company's stock is undervalued or that the company's prospects are strong.

Stakeholder Impact

• Shareholders may view the insider buying as a positive signal, potentially increasing confidence in the company.

Key Dates